Գլյուկագոնանման պեպտիդ-1 ընկալիչների ագոնիստներ (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Գլյուկագոնանման պեպտիդ-1 ընկալիչների ագոնիստներ" in Armenian language version.

refsWebsite

Global rank Armenian rank

37nih.gov

4^th place

3^rd place

26doi.org

2^nd place

4^th place

15semanticscholar.org

11^th place

428^th place

11worldcat.org

5^th place

10^th place

3fda.gov

447^th place

244^th place

2tandfonline.com

507^th place

468^th place

2sciencedirect.com

149^th place

260^th place

2web.archive.org

1^st place

1rug.nl

2,779^th place

2,930^th place

1gla.ac.uk

2,948^th place

3,578^th place

1springer.com

274^th place

266^th place

1nbcnews.com

137^th place

1,108^th place

1asahq.org

low place

1medscape.com

719^th place

149^th place

asahq.org

American Society of Anesthesiologists Consensus, 2023.«American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists».

doi.org

Drucker, Daniel J. (2022). «GLP-1 physiology informs the pharmacotherapy of obesity». Molecular Metabolism (Review). Elsevier. 57: 101351. doi:10.1016/j.molmet.2021.101351. ISSN 2212-8778. PMC 8859548. PMID 34626851.
Brunton, Stephen. «GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes». International Journal of Clinical Practice (Review). Wiley. 68 (5): 557–567. doi:10.1111/ijcp.12361. PMC 4238422. PMID 24499291.
Shao, Weijuan; Jin, Tianru (2022). «Hepatic hormone FGF21 and its analogues in clinical trials». Chronic Diseases and Translational Medicine (Review) (անգլերեն). Wiley. 8 (1): 19–25. doi:10.1016/j.cdtm.2021.08.005. ISSN 2589-0514. PMC 9126297 – via Wiley Online Library.
Brown, Emily; Heerspink, Hiddo J L; Cuthbertson, Daniel J; Wilding, John P H (2021). «SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications» (PDF). The Lancet (Review). 398 (10296): 262–276. doi:10.1016/S0140-6736(21)00536-5. PMID 34216571. S2CID 235691785 – via University of Groningen.
Nachawi, Noura; Rao, Pratibha PR; Makin, Vinni (2022). «The role of GLP-1 receptor agonists in managing type 2 diabetes». Cleveland Clinic Journal of Medicine (Review). 89 (8): 457–464. doi:10.3949/ccjm.89a.21110. PMID 35914933. S2CID 251227696.
American Diabetes Association Professional Practice Committee (January 2022). «9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022». Diabetes Care. American Diabetes Association. 45 (Suppl 1): S125–S143. doi:10.2337/dc22-S009. PMID 34964831. S2CID 245538347.
American Diabetes Association (January 2012). «Standards of medical care in diabetes--2012». Diabetes Care (Position Statement). 35 (Suppl 1): S11–S63. doi:10.2337/dc12-s011. PMC 3632172. PMID 22187469.
Sattar, Naveed; Lee, Matthew M Y; Kristensen, Søren L; Branch, Kelley R H; Del Prato, Stefano; Khurmi, Nardev S; Lam, Carolyn S P; Lopes, Renato D; McMurray, John J V; Pratley, Richard E; Rosenstock, Julio; Gerstein, Hertzel C (2021). «Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials» (PDF). The Lancet Diabetes & Endocrinology. 9 (10): 653–662. doi:10.1016/s2213-8587(21)00203-5. PMID 34425083. S2CID 237281403 – via Enlighten: Publications.
Sohn, Minji; Dietrich, Johannes W.; Nauck, Michael A.; Lim, Soo (2023). «Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study». Cardiovascular Diabetology (Research). BioMed Central. 22 (1): 153. doi:10.1186/s12933-023-01877-6. PMC 10303335. PMID 37381019.
DeFronzo, Ralph A. (2017). «Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor». Diabetes, Obesity & Metabolism (Review). Wiley. 19 (10): 1353–1362. doi:10.1111/dom.12982. ISSN 1463-1326. PMC 5643008. PMID 28432726.
Pedrosa, Maurício Reis; Franco, Denise Reis; Gieremek, Hannah Waisberg; Vidal, Camila Maia; Bronzeri, Fernanda; de Cassia Rocha, Alexia; de Carvalho Cara, Luis Gabriel; Fogo, Sofia Lenzi; Eliaschewitz, Freddy Goldberg (2022). «GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?». Current Atherosclerosis Reports (Review) (անգլերեն). Springer Nature. 24 (11): 867–884. doi:10.1007/s11883-022-01062-2. ISSN 1534-6242. PMID 36044100. S2CID 251934466.
Wharton, Sean; Davies, Melanie; Dicker, Dror; Lingvay, Ildiko; Mosenzon, Ofri; Rubino, Domenica M.; Pedersen, Sue D. (2022). «Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice». Postgraduate Medicine (Commentary) (անգլերեն). 134 (1): 14–19. doi:10.1080/00325481.2021.2002616. ISSN 0032-5481. PMID 34775881. S2CID 244116070.
Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. (March 2022). «Anti-obesity drug discovery: advances and challenges». Nature Reviews Drug Discovery (Review) (անգլերեն). 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. ISSN 1474-1784. PMC 8609996. PMID 34815532.
Grill, Harvey J (2020). «A Role for GLP-1 in Treating Hyperphagia and Obesity». Endocrinology (Article). Oxford Academic. 161 (8). doi:10.1210/endocr/bqaa093. PMC 7899438. PMID 32516384.
Gu, Yunpeng; Sun, Lei; He, Yining; Yang, Luping; Deng, Chaohua; Zhou, Run; Kong, Tingting; Zhang, Wei; Chen, Yutong; Li, Jie; Shi, Junping (2023 թ․ մարտի 4). «Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials». Expert Review of Gastroenterology & Hepatology (Systematic Review and Meta-analysis). Taylor & Francis. 17 (3): 273–282. doi:10.1080/17474124.2023.2172397. PMID 36689199.
Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). «Clinical Trial Landscape in NASH». Clinical Gastroenterology and Hepatology (Review). Elsevier. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041. PMID 37059159. S2CID 258115543.
Siamashvili, Maka; Davis, Stephen N. (2021). «Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome». Expert Review of Clinical Pharmacology (Review) (անգլերեն). Taylor & Francis. 14 (9): 1081–1089. doi:10.1080/17512433.2021.1933433. ISSN 1751-2433. PMID 34015974. S2CID 235073455.
Cooper, Daniel H.; Ramachandra, Ranuk; Ceban, Felicia; Di Vincenzo, Joshua D.; Rhee, Taeho Greg; Mansur, Rodrigo B.; Teopiz, Kayla M.; Gill, Hartej; Ho, Roger; Cao, Bing; Lui, Leanna M. W.; Jawad, Muhammad Youshay; Arsenault, Juliet; Le, Gia Han; Ramachandra, Diluk; Guo, Ziji; McIntyre, Roger S. (2023). «Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus». Journal of Psychiatric Research (Systematic review). Elsevier. 164: 80–89. doi:10.1016/j.jpsychires.2023.05.041. ISSN 0022-3956. PMID 37331261. S2CID 259193871.
Pozzi, Marco; Mazhar, Faizan; Peeters, Gabriëlla G. A. M.; Vantaggiato, Chiara; Nobile, Maria; Clementi, Emilio; Radice, Sonia; Carnovale, Carla (2019). «A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists». Journal of Affective Disorders (Systematic review). Elsevier. 257: 774–778. doi:10.1016/j.jad.2019.05.044. ISSN 0165-0327. PMID 31153593. S2CID 173994595.
Knerr, Patrick J.; Mowery, Stephanie A.; Finan, Brian; Perez-Tilve, Diego; Tschöp, Matthias H.; DiMarchi, Richard D. (2020). «Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates». Peptides (անգլերեն). 125: 170225. doi:10.1016/j.peptides.2019.170225. PMID 31786282. S2CID 208331348.
Yu, Minzhi; Benjamin, Mason M.; Srinivasan, Santhanakrishnan; Morin, Emily E.; Shishatskaya, Ekaterina I.; Schwendeman, Steven P.; Schwendeman, Anna (2018). «Battle of GLP-1 delivery technologies». Advanced Drug Delivery Reviews. 130: 113–130. doi:10.1016/j.addr.2018.07.009. PMC 6843995. PMID 30009885.
Antza, Christina; Nirantharakumar, Krishnarajah; Doundoulakis, Ioannis; Tahrani, Abd A.; Toulis, Konstantinos A. (2019). «The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date». Drug Design, Development and Therapy (English). 13: 2985–2996. doi:10.2147/DDDT.S166765. PMC 6709822. PMID 31686781.{{cite journal}}: CS1 սպաս․ չճանաչված լեզու (link)
Yang, Chun-Ting; Yao, Wen-Yu; Ou, Huang-Tz; Kuo, Shihchen (April 2023). «Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data». Diabetes Research and Clinical Practice. 198: 110625. doi:10.1016/j.diabres.2023.110625. ISSN 1872-8227. PMID 36924833. S2CID 257572519.
Moore, Peyton W.; Malone, Kevin; VanValkenburg, Delena; Rando, Lauren L.; Williams, Brooke C.; Matejowsky, Hannah G.; Ahmadzadeh, Shahab; Shekoohi, Sahar; Cornett, Elyse M.; Kaye, Alan D. (2023). «GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications». Advances in Therapy. 40 (3): 723–742. doi:10.1007/s12325-022-02394-w. PMID 36566341. S2CID 255117019.
Tibble CA, Cavaiola TS, Henry RR (2014 թ․ հունվարի 10). «Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature». Expert Review of Endocrinology & Metabolism. Taylor & Francis. 8 (3): 247–259. doi:10.1586/eem.13.20. eISSN 1744-8417. ISSN 1744-6651. PMID 30780817. S2CID 73313508.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, և այլք: (August 2021). «Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes». The New England Journal of Medicine. 385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647. S2CID 235635529.

fda.gov

«FDA Approves New Treatment for Type 2 Diabetes» (Press release). Food and Drug Administration. 2010 թ․ հունվարի 25. Արխիվացված է օրիգինալից 2010 թ․ հունվարի 28-ին.
«FDA approves Trulicity to treat type 2 diabetes» (Press release). Food and Drug Administration. 2014 թ․ սեպտեմբերի 18. Արխիվացված է օրիգինալից 2014 թ․ սեպտեմբերի 18-ին.
«FDA approves Adlyxin to treat type 2 diabetes» (Press release). Food and Drug Administration. 2016 թ․ հուլիսի 28.

gla.ac.uk

eprints.gla.ac.uk

Sattar, Naveed; Lee, Matthew M Y; Kristensen, Søren L; Branch, Kelley R H; Del Prato, Stefano; Khurmi, Nardev S; Lam, Carolyn S P; Lopes, Renato D; McMurray, John J V; Pratley, Richard E; Rosenstock, Julio; Gerstein, Hertzel C (2021). «Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials» (PDF). The Lancet Diabetes & Endocrinology. 9 (10): 653–662. doi:10.1016/s2213-8587(21)00203-5. PMID 34425083. S2CID 237281403 – via Enlighten: Publications.

medscape.com

Busko, Marlene (2014 թ․ ապրիլի 15). «FDA Approves Weekly Injectable Diabetes Drug: Albiglutide». Medscape (News, FDA Approvals).

nbcnews.com

Hopkins, Caroline (2023 թ․ հունիսի 24). «Researchers keep discovering new uses for Ozempic. Proving it works isn't easy». Health News. NBC News (անգլերեն). Վերցված է 2023 թ․ դեկտեմբերի 26-ին.

nih.gov

pubmed.ncbi.nlm.nih.gov

Latif, Wafa; Lambrinos, Katerina J.; Rodriguez, Rolando (27 March 2023), «Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)», StatPearls, Treasure Island, Florida: StatPearls Publishing, PMID 34283517, Վերցված է 26 December 2023-ին – via NCBI Bookshelf
Drucker, Daniel J. (2022). «GLP-1 physiology informs the pharmacotherapy of obesity». Molecular Metabolism (Review). Elsevier. 57: 101351. doi:10.1016/j.molmet.2021.101351. ISSN 2212-8778. PMC 8859548. PMID 34626851.
Brunton, Stephen. «GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes». International Journal of Clinical Practice (Review). Wiley. 68 (5): 557–567. doi:10.1111/ijcp.12361. PMC 4238422. PMID 24499291.
Brown, Emily; Heerspink, Hiddo J L; Cuthbertson, Daniel J; Wilding, John P H (2021). «SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications» (PDF). The Lancet (Review). 398 (10296): 262–276. doi:10.1016/S0140-6736(21)00536-5. PMID 34216571. S2CID 235691785 – via University of Groningen.
Nachawi, Noura; Rao, Pratibha PR; Makin, Vinni (2022). «The role of GLP-1 receptor agonists in managing type 2 diabetes». Cleveland Clinic Journal of Medicine (Review). 89 (8): 457–464. doi:10.3949/ccjm.89a.21110. PMID 35914933. S2CID 251227696.
American Diabetes Association Professional Practice Committee (January 2022). «9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022». Diabetes Care. American Diabetes Association. 45 (Suppl 1): S125–S143. doi:10.2337/dc22-S009. PMID 34964831. S2CID 245538347.
American Diabetes Association (January 2012). «Standards of medical care in diabetes--2012». Diabetes Care (Position Statement). 35 (Suppl 1): S11–S63. doi:10.2337/dc12-s011. PMC 3632172. PMID 22187469.
Sattar, Naveed; Lee, Matthew M Y; Kristensen, Søren L; Branch, Kelley R H; Del Prato, Stefano; Khurmi, Nardev S; Lam, Carolyn S P; Lopes, Renato D; McMurray, John J V; Pratley, Richard E; Rosenstock, Julio; Gerstein, Hertzel C (2021). «Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials» (PDF). The Lancet Diabetes & Endocrinology. 9 (10): 653–662. doi:10.1016/s2213-8587(21)00203-5. PMID 34425083. S2CID 237281403 – via Enlighten: Publications.
Sohn, Minji; Dietrich, Johannes W.; Nauck, Michael A.; Lim, Soo (2023). «Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study». Cardiovascular Diabetology (Research). BioMed Central. 22 (1): 153. doi:10.1186/s12933-023-01877-6. PMC 10303335. PMID 37381019.
DeFronzo, Ralph A. (2017). «Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor». Diabetes, Obesity & Metabolism (Review). Wiley. 19 (10): 1353–1362. doi:10.1111/dom.12982. ISSN 1463-1326. PMC 5643008. PMID 28432726.
Pedrosa, Maurício Reis; Franco, Denise Reis; Gieremek, Hannah Waisberg; Vidal, Camila Maia; Bronzeri, Fernanda; de Cassia Rocha, Alexia; de Carvalho Cara, Luis Gabriel; Fogo, Sofia Lenzi; Eliaschewitz, Freddy Goldberg (2022). «GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?». Current Atherosclerosis Reports (Review) (անգլերեն). Springer Nature. 24 (11): 867–884. doi:10.1007/s11883-022-01062-2. ISSN 1534-6242. PMID 36044100. S2CID 251934466.
Wharton, Sean; Davies, Melanie; Dicker, Dror; Lingvay, Ildiko; Mosenzon, Ofri; Rubino, Domenica M.; Pedersen, Sue D. (2022). «Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice». Postgraduate Medicine (Commentary) (անգլերեն). 134 (1): 14–19. doi:10.1080/00325481.2021.2002616. ISSN 0032-5481. PMID 34775881. S2CID 244116070.
Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. (March 2022). «Anti-obesity drug discovery: advances and challenges». Nature Reviews Drug Discovery (Review) (անգլերեն). 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. ISSN 1474-1784. PMC 8609996. PMID 34815532.
Grill, Harvey J (2020). «A Role for GLP-1 in Treating Hyperphagia and Obesity». Endocrinology (Article). Oxford Academic. 161 (8). doi:10.1210/endocr/bqaa093. PMC 7899438. PMID 32516384.
Gu, Yunpeng; Sun, Lei; He, Yining; Yang, Luping; Deng, Chaohua; Zhou, Run; Kong, Tingting; Zhang, Wei; Chen, Yutong; Li, Jie; Shi, Junping (2023 թ․ մարտի 4). «Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials». Expert Review of Gastroenterology & Hepatology (Systematic Review and Meta-analysis). Taylor & Francis. 17 (3): 273–282. doi:10.1080/17474124.2023.2172397. PMID 36689199.
Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). «Clinical Trial Landscape in NASH». Clinical Gastroenterology and Hepatology (Review). Elsevier. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041. PMID 37059159. S2CID 258115543.
Siamashvili, Maka; Davis, Stephen N. (2021). «Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome». Expert Review of Clinical Pharmacology (Review) (անգլերեն). Taylor & Francis. 14 (9): 1081–1089. doi:10.1080/17512433.2021.1933433. ISSN 1751-2433. PMID 34015974. S2CID 235073455.
Cooper, Daniel H.; Ramachandra, Ranuk; Ceban, Felicia; Di Vincenzo, Joshua D.; Rhee, Taeho Greg; Mansur, Rodrigo B.; Teopiz, Kayla M.; Gill, Hartej; Ho, Roger; Cao, Bing; Lui, Leanna M. W.; Jawad, Muhammad Youshay; Arsenault, Juliet; Le, Gia Han; Ramachandra, Diluk; Guo, Ziji; McIntyre, Roger S. (2023). «Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus». Journal of Psychiatric Research (Systematic review). Elsevier. 164: 80–89. doi:10.1016/j.jpsychires.2023.05.041. ISSN 0022-3956. PMID 37331261. S2CID 259193871.
Pozzi, Marco; Mazhar, Faizan; Peeters, Gabriëlla G. A. M.; Vantaggiato, Chiara; Nobile, Maria; Clementi, Emilio; Radice, Sonia; Carnovale, Carla (2019). «A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists». Journal of Affective Disorders (Systematic review). Elsevier. 257: 774–778. doi:10.1016/j.jad.2019.05.044. ISSN 0165-0327. PMID 31153593. S2CID 173994595.
Knerr, Patrick J.; Mowery, Stephanie A.; Finan, Brian; Perez-Tilve, Diego; Tschöp, Matthias H.; DiMarchi, Richard D. (2020). «Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates». Peptides (անգլերեն). 125: 170225. doi:10.1016/j.peptides.2019.170225. PMID 31786282. S2CID 208331348.
Yu, Minzhi; Benjamin, Mason M.; Srinivasan, Santhanakrishnan; Morin, Emily E.; Shishatskaya, Ekaterina I.; Schwendeman, Steven P.; Schwendeman, Anna (2018). «Battle of GLP-1 delivery technologies». Advanced Drug Delivery Reviews. 130: 113–130. doi:10.1016/j.addr.2018.07.009. PMC 6843995. PMID 30009885.
Antza, Christina; Nirantharakumar, Krishnarajah; Doundoulakis, Ioannis; Tahrani, Abd A.; Toulis, Konstantinos A. (2019). «The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date». Drug Design, Development and Therapy (English). 13: 2985–2996. doi:10.2147/DDDT.S166765. PMC 6709822. PMID 31686781.{{cite journal}}: CS1 սպաս․ չճանաչված լեզու (link)
Yang, Chun-Ting; Yao, Wen-Yu; Ou, Huang-Tz; Kuo, Shihchen (April 2023). «Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data». Diabetes Research and Clinical Practice. 198: 110625. doi:10.1016/j.diabres.2023.110625. ISSN 1872-8227. PMID 36924833. S2CID 257572519.
Moore, Peyton W.; Malone, Kevin; VanValkenburg, Delena; Rando, Lauren L.; Williams, Brooke C.; Matejowsky, Hannah G.; Ahmadzadeh, Shahab; Shekoohi, Sahar; Cornett, Elyse M.; Kaye, Alan D. (2023). «GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications». Advances in Therapy. 40 (3): 723–742. doi:10.1007/s12325-022-02394-w. PMID 36566341. S2CID 255117019.
Tibble CA, Cavaiola TS, Henry RR (2014 թ․ հունվարի 10). «Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature». Expert Review of Endocrinology & Metabolism. Taylor & Francis. 8 (3): 247–259. doi:10.1586/eem.13.20. eISSN 1744-8417. ISSN 1744-6651. PMID 30780817. S2CID 73313508.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, և այլք: (August 2021). «Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes». The New England Journal of Medicine. 385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647. S2CID 235635529.

ncbi.nlm.nih.gov

Latif, Wafa; Lambrinos, Katerina J.; Rodriguez, Rolando (27 March 2023), «Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)», StatPearls, Treasure Island, Florida: StatPearls Publishing, PMID 34283517, Վերցված է 26 December 2023-ին – via NCBI Bookshelf
Drucker, Daniel J. (2022). «GLP-1 physiology informs the pharmacotherapy of obesity». Molecular Metabolism (Review). Elsevier. 57: 101351. doi:10.1016/j.molmet.2021.101351. ISSN 2212-8778. PMC 8859548. PMID 34626851.
Brunton, Stephen. «GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes». International Journal of Clinical Practice (Review). Wiley. 68 (5): 557–567. doi:10.1111/ijcp.12361. PMC 4238422. PMID 24499291.
Shao, Weijuan; Jin, Tianru (2022). «Hepatic hormone FGF21 and its analogues in clinical trials». Chronic Diseases and Translational Medicine (Review) (անգլերեն). Wiley. 8 (1): 19–25. doi:10.1016/j.cdtm.2021.08.005. ISSN 2589-0514. PMC 9126297 – via Wiley Online Library.
American Diabetes Association (January 2012). «Standards of medical care in diabetes--2012». Diabetes Care (Position Statement). 35 (Suppl 1): S11–S63. doi:10.2337/dc12-s011. PMC 3632172. PMID 22187469.
Sohn, Minji; Dietrich, Johannes W.; Nauck, Michael A.; Lim, Soo (2023). «Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study». Cardiovascular Diabetology (Research). BioMed Central. 22 (1): 153. doi:10.1186/s12933-023-01877-6. PMC 10303335. PMID 37381019.
DeFronzo, Ralph A. (2017). «Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor». Diabetes, Obesity & Metabolism (Review). Wiley. 19 (10): 1353–1362. doi:10.1111/dom.12982. ISSN 1463-1326. PMC 5643008. PMID 28432726.
Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. (March 2022). «Anti-obesity drug discovery: advances and challenges». Nature Reviews Drug Discovery (Review) (անգլերեն). 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. ISSN 1474-1784. PMC 8609996. PMID 34815532.
Grill, Harvey J (2020). «A Role for GLP-1 in Treating Hyperphagia and Obesity». Endocrinology (Article). Oxford Academic. 161 (8). doi:10.1210/endocr/bqaa093. PMC 7899438. PMID 32516384.
Yu, Minzhi; Benjamin, Mason M.; Srinivasan, Santhanakrishnan; Morin, Emily E.; Shishatskaya, Ekaterina I.; Schwendeman, Steven P.; Schwendeman, Anna (2018). «Battle of GLP-1 delivery technologies». Advanced Drug Delivery Reviews. 130: 113–130. doi:10.1016/j.addr.2018.07.009. PMC 6843995. PMID 30009885.
Antza, Christina; Nirantharakumar, Krishnarajah; Doundoulakis, Ioannis; Tahrani, Abd A.; Toulis, Konstantinos A. (2019). «The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date». Drug Design, Development and Therapy (English). 13: 2985–2996. doi:10.2147/DDDT.S166765. PMC 6709822. PMID 31686781.{{cite journal}}: CS1 սպաս․ չճանաչված լեզու (link)

rug.nl

pure.rug.nl

Brown, Emily; Heerspink, Hiddo J L; Cuthbertson, Daniel J; Wilding, John P H (2021). «SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications» (PDF). The Lancet (Review). 398 (10296): 262–276. doi:10.1016/S0140-6736(21)00536-5. PMID 34216571. S2CID 235691785 – via University of Groningen.

sciencedirect.com

Cooper, Daniel H.; Ramachandra, Ranuk; Ceban, Felicia; Di Vincenzo, Joshua D.; Rhee, Taeho Greg; Mansur, Rodrigo B.; Teopiz, Kayla M.; Gill, Hartej; Ho, Roger; Cao, Bing; Lui, Leanna M. W.; Jawad, Muhammad Youshay; Arsenault, Juliet; Le, Gia Han; Ramachandra, Diluk; Guo, Ziji; McIntyre, Roger S. (2023). «Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus». Journal of Psychiatric Research (Systematic review). Elsevier. 164: 80–89. doi:10.1016/j.jpsychires.2023.05.041. ISSN 0022-3956. PMID 37331261. S2CID 259193871.
Pozzi, Marco; Mazhar, Faizan; Peeters, Gabriëlla G. A. M.; Vantaggiato, Chiara; Nobile, Maria; Clementi, Emilio; Radice, Sonia; Carnovale, Carla (2019). «A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists». Journal of Affective Disorders (Systematic review). Elsevier. 257: 774–778. doi:10.1016/j.jad.2019.05.044. ISSN 0165-0327. PMID 31153593. S2CID 173994595.

semanticscholar.org

api.semanticscholar.org

Brown, Emily; Heerspink, Hiddo J L; Cuthbertson, Daniel J; Wilding, John P H (2021). «SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications» (PDF). The Lancet (Review). 398 (10296): 262–276. doi:10.1016/S0140-6736(21)00536-5. PMID 34216571. S2CID 235691785 – via University of Groningen.
Nachawi, Noura; Rao, Pratibha PR; Makin, Vinni (2022). «The role of GLP-1 receptor agonists in managing type 2 diabetes». Cleveland Clinic Journal of Medicine (Review). 89 (8): 457–464. doi:10.3949/ccjm.89a.21110. PMID 35914933. S2CID 251227696.
American Diabetes Association Professional Practice Committee (January 2022). «9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022». Diabetes Care. American Diabetes Association. 45 (Suppl 1): S125–S143. doi:10.2337/dc22-S009. PMID 34964831. S2CID 245538347.
Sattar, Naveed; Lee, Matthew M Y; Kristensen, Søren L; Branch, Kelley R H; Del Prato, Stefano; Khurmi, Nardev S; Lam, Carolyn S P; Lopes, Renato D; McMurray, John J V; Pratley, Richard E; Rosenstock, Julio; Gerstein, Hertzel C (2021). «Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials» (PDF). The Lancet Diabetes & Endocrinology. 9 (10): 653–662. doi:10.1016/s2213-8587(21)00203-5. PMID 34425083. S2CID 237281403 – via Enlighten: Publications.
Pedrosa, Maurício Reis; Franco, Denise Reis; Gieremek, Hannah Waisberg; Vidal, Camila Maia; Bronzeri, Fernanda; de Cassia Rocha, Alexia; de Carvalho Cara, Luis Gabriel; Fogo, Sofia Lenzi; Eliaschewitz, Freddy Goldberg (2022). «GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?». Current Atherosclerosis Reports (Review) (անգլերեն). Springer Nature. 24 (11): 867–884. doi:10.1007/s11883-022-01062-2. ISSN 1534-6242. PMID 36044100. S2CID 251934466.
Wharton, Sean; Davies, Melanie; Dicker, Dror; Lingvay, Ildiko; Mosenzon, Ofri; Rubino, Domenica M.; Pedersen, Sue D. (2022). «Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice». Postgraduate Medicine (Commentary) (անգլերեն). 134 (1): 14–19. doi:10.1080/00325481.2021.2002616. ISSN 0032-5481. PMID 34775881. S2CID 244116070.
Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). «Clinical Trial Landscape in NASH». Clinical Gastroenterology and Hepatology (Review). Elsevier. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041. PMID 37059159. S2CID 258115543.
Siamashvili, Maka; Davis, Stephen N. (2021). «Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome». Expert Review of Clinical Pharmacology (Review) (անգլերեն). Taylor & Francis. 14 (9): 1081–1089. doi:10.1080/17512433.2021.1933433. ISSN 1751-2433. PMID 34015974. S2CID 235073455.
Cooper, Daniel H.; Ramachandra, Ranuk; Ceban, Felicia; Di Vincenzo, Joshua D.; Rhee, Taeho Greg; Mansur, Rodrigo B.; Teopiz, Kayla M.; Gill, Hartej; Ho, Roger; Cao, Bing; Lui, Leanna M. W.; Jawad, Muhammad Youshay; Arsenault, Juliet; Le, Gia Han; Ramachandra, Diluk; Guo, Ziji; McIntyre, Roger S. (2023). «Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus». Journal of Psychiatric Research (Systematic review). Elsevier. 164: 80–89. doi:10.1016/j.jpsychires.2023.05.041. ISSN 0022-3956. PMID 37331261. S2CID 259193871.
Pozzi, Marco; Mazhar, Faizan; Peeters, Gabriëlla G. A. M.; Vantaggiato, Chiara; Nobile, Maria; Clementi, Emilio; Radice, Sonia; Carnovale, Carla (2019). «A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists». Journal of Affective Disorders (Systematic review). Elsevier. 257: 774–778. doi:10.1016/j.jad.2019.05.044. ISSN 0165-0327. PMID 31153593. S2CID 173994595.
Knerr, Patrick J.; Mowery, Stephanie A.; Finan, Brian; Perez-Tilve, Diego; Tschöp, Matthias H.; DiMarchi, Richard D. (2020). «Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates». Peptides (անգլերեն). 125: 170225. doi:10.1016/j.peptides.2019.170225. PMID 31786282. S2CID 208331348.
Yang, Chun-Ting; Yao, Wen-Yu; Ou, Huang-Tz; Kuo, Shihchen (April 2023). «Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data». Diabetes Research and Clinical Practice. 198: 110625. doi:10.1016/j.diabres.2023.110625. ISSN 1872-8227. PMID 36924833. S2CID 257572519.
Moore, Peyton W.; Malone, Kevin; VanValkenburg, Delena; Rando, Lauren L.; Williams, Brooke C.; Matejowsky, Hannah G.; Ahmadzadeh, Shahab; Shekoohi, Sahar; Cornett, Elyse M.; Kaye, Alan D. (2023). «GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications». Advances in Therapy. 40 (3): 723–742. doi:10.1007/s12325-022-02394-w. PMID 36566341. S2CID 255117019.
Tibble CA, Cavaiola TS, Henry RR (2014 թ․ հունվարի 10). «Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature». Expert Review of Endocrinology & Metabolism. Taylor & Francis. 8 (3): 247–259. doi:10.1586/eem.13.20. eISSN 1744-8417. ISSN 1744-6651. PMID 30780817. S2CID 73313508.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, և այլք: (August 2021). «Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes». The New England Journal of Medicine. 385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647. S2CID 235635529.

springer.com

link.springer.com

Pedrosa, Maurício Reis; Franco, Denise Reis; Gieremek, Hannah Waisberg; Vidal, Camila Maia; Bronzeri, Fernanda; de Cassia Rocha, Alexia; de Carvalho Cara, Luis Gabriel; Fogo, Sofia Lenzi; Eliaschewitz, Freddy Goldberg (2022). «GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?». Current Atherosclerosis Reports (Review) (անգլերեն). Springer Nature. 24 (11): 867–884. doi:10.1007/s11883-022-01062-2. ISSN 1534-6242. PMID 36044100. S2CID 251934466.

tandfonline.com

Gu, Yunpeng; Sun, Lei; He, Yining; Yang, Luping; Deng, Chaohua; Zhou, Run; Kong, Tingting; Zhang, Wei; Chen, Yutong; Li, Jie; Shi, Junping (2023 թ․ մարտի 4). «Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials». Expert Review of Gastroenterology & Hepatology (Systematic Review and Meta-analysis). Taylor & Francis. 17 (3): 273–282. doi:10.1080/17474124.2023.2172397. PMID 36689199.
Tibble CA, Cavaiola TS, Henry RR (2014 թ․ հունվարի 10). «Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature». Expert Review of Endocrinology & Metabolism. Taylor & Francis. 8 (3): 247–259. doi:10.1586/eem.13.20. eISSN 1744-8417. ISSN 1744-6651. PMID 30780817. S2CID 73313508.

web.archive.org

«FDA Approves New Treatment for Type 2 Diabetes» (Press release). Food and Drug Administration. 2010 թ․ հունվարի 25. Արխիվացված է օրիգինալից 2010 թ․ հունվարի 28-ին.
«FDA approves Trulicity to treat type 2 diabetes» (Press release). Food and Drug Administration. 2014 թ․ սեպտեմբերի 18. Արխիվացված է օրիգինալից 2014 թ․ սեպտեմբերի 18-ին.

worldcat.org

Drucker, Daniel J. (2022). «GLP-1 physiology informs the pharmacotherapy of obesity». Molecular Metabolism (Review). Elsevier. 57: 101351. doi:10.1016/j.molmet.2021.101351. ISSN 2212-8778. PMC 8859548. PMID 34626851.
Shao, Weijuan; Jin, Tianru (2022). «Hepatic hormone FGF21 and its analogues in clinical trials». Chronic Diseases and Translational Medicine (Review) (անգլերեն). Wiley. 8 (1): 19–25. doi:10.1016/j.cdtm.2021.08.005. ISSN 2589-0514. PMC 9126297 – via Wiley Online Library.
DeFronzo, Ralph A. (2017). «Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor». Diabetes, Obesity & Metabolism (Review). Wiley. 19 (10): 1353–1362. doi:10.1111/dom.12982. ISSN 1463-1326. PMC 5643008. PMID 28432726.
Pedrosa, Maurício Reis; Franco, Denise Reis; Gieremek, Hannah Waisberg; Vidal, Camila Maia; Bronzeri, Fernanda; de Cassia Rocha, Alexia; de Carvalho Cara, Luis Gabriel; Fogo, Sofia Lenzi; Eliaschewitz, Freddy Goldberg (2022). «GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?». Current Atherosclerosis Reports (Review) (անգլերեն). Springer Nature. 24 (11): 867–884. doi:10.1007/s11883-022-01062-2. ISSN 1534-6242. PMID 36044100. S2CID 251934466.
Wharton, Sean; Davies, Melanie; Dicker, Dror; Lingvay, Ildiko; Mosenzon, Ofri; Rubino, Domenica M.; Pedersen, Sue D. (2022). «Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice». Postgraduate Medicine (Commentary) (անգլերեն). 134 (1): 14–19. doi:10.1080/00325481.2021.2002616. ISSN 0032-5481. PMID 34775881. S2CID 244116070.
Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. (March 2022). «Anti-obesity drug discovery: advances and challenges». Nature Reviews Drug Discovery (Review) (անգլերեն). 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. ISSN 1474-1784. PMC 8609996. PMID 34815532.
Siamashvili, Maka; Davis, Stephen N. (2021). «Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome». Expert Review of Clinical Pharmacology (Review) (անգլերեն). Taylor & Francis. 14 (9): 1081–1089. doi:10.1080/17512433.2021.1933433. ISSN 1751-2433. PMID 34015974. S2CID 235073455.
Cooper, Daniel H.; Ramachandra, Ranuk; Ceban, Felicia; Di Vincenzo, Joshua D.; Rhee, Taeho Greg; Mansur, Rodrigo B.; Teopiz, Kayla M.; Gill, Hartej; Ho, Roger; Cao, Bing; Lui, Leanna M. W.; Jawad, Muhammad Youshay; Arsenault, Juliet; Le, Gia Han; Ramachandra, Diluk; Guo, Ziji; McIntyre, Roger S. (2023). «Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus». Journal of Psychiatric Research (Systematic review). Elsevier. 164: 80–89. doi:10.1016/j.jpsychires.2023.05.041. ISSN 0022-3956. PMID 37331261. S2CID 259193871.
Pozzi, Marco; Mazhar, Faizan; Peeters, Gabriëlla G. A. M.; Vantaggiato, Chiara; Nobile, Maria; Clementi, Emilio; Radice, Sonia; Carnovale, Carla (2019). «A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists». Journal of Affective Disorders (Systematic review). Elsevier. 257: 774–778. doi:10.1016/j.jad.2019.05.044. ISSN 0165-0327. PMID 31153593. S2CID 173994595.
Yang, Chun-Ting; Yao, Wen-Yu; Ou, Huang-Tz; Kuo, Shihchen (April 2023). «Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data». Diabetes Research and Clinical Practice. 198: 110625. doi:10.1016/j.diabres.2023.110625. ISSN 1872-8227. PMID 36924833. S2CID 257572519.
Tibble CA, Cavaiola TS, Henry RR (2014 թ․ հունվարի 10). «Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature». Expert Review of Endocrinology & Metabolism. Taylor & Francis. 8 (3): 247–259. doi:10.1586/eem.13.20. eISSN 1744-8417. ISSN 1744-6651. PMID 30780817. S2CID 73313508.